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Assessing the Temporal Course of
Neointimal Hyperplasia Formation After
Different Generations of Drug-Eluting Stents
Carlos A. Collet, MD, J. Ribamar Costa, MD, Alexandre Abizaid, MD, PHD,
Daniel Chamié, MD, Rodolfo Staico, MD, Ricardo Costa, MD, Dimytri Siquera, MD,
Javier Obregon, MD, Fausto Feres, MD, PHD, Amanda Sousa, MD, PHD,
Jose Eduardo Sousa, MD, PHD
São Paulo, Brazil
Objectives This study sought to assess the temporal course of neointimal hyperplasia (NIH) forma-
tion following implantation of 2 different generations of drug-eluting stents (DES).
Background The amount of NIH following DES implantation correlates with the potency of the anti-
proliferative drug, its kinetic release, as well as some individual characteristics, as the presence of
diabetes mellitus (DM). Recently, some publications have suggested a continuous growth of NIH fol-
lowing DES, which in some cases, might result in late “catch-up.”
Methods Twenty-ﬁve patients with single, de novo lesions were treated with sirolimus-eluting
stents (SES) (n  12) and biolimus-eluting stents (BES) (n  13) and underwent intravascular ultra-
sound evaluation immediately after the procedure and at 9-month and 5-year follow-ups. The pri-
mary endpoint was the comparison of the percentage of NIH obstruction between mid- and long-
term follow-up.
Results Mean age was 59 years and 28% of patients had DM. Overall, the percentage of NIH ob-
struction signiﬁcantly increased from 9 months to 5 years (1.3% at ﬁrst follow-up vs. 4.8% at second
follow-up, p  0.002). There was no signiﬁcant difference in the variation of vessel volume (∆ 
0.70 mm3/mm BES vs. ∆  0.18 mm3/mm SES, p  0.56), lumen volume (∆  0.40 mm3/mm BES
s. ∆  0.05 mm3/mm SES, p  0.71), and percentage of NIH obstruction (∆  3.0% BES vs. ∆ 
3.8% SES, p  0.55) among DES. However, diabetic patients had a marked NIH increase along the
years (NIH volume at second follow-up: 10.15 mm3 DM vs. 5.11 mm3 non-DM, p  0.028).
Conclusions The present serial intravascular ultrasound assessment supports the occurrence of con-
tinuous NIH growth following different generations of DES. These ﬁndings seem to be particularly
more pronounced among patients with DM. (J Am Coll Cardiol Intv 2011;4:1067–74) © 2011 by the
American College of Cardiology Foundation
From the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The authors have reported that they have no relationships
relevant to the contents of this paper to disclose.Manuscript received February 2, 2011; revised manuscript received July 12, 2011, accepted July 21, 2011.
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1068Achievement of effective neointimal hyperplasia (NIH)
suppression after drug-eluting stent (DES) placement was a
major breakthrough in interventional cardiology, diminish-
ing rates of restenosis and target lesion revascularization
(TLR) (1,2). Nevertheless, contemporary DES technology
has a limited period of evaluation and very long-term
invasive follow-up is still not available, in particular for
second-generation DES.
See page 1075
Recent publications have suggested a continuous growth
of NIH following DES placement, which in some cases,
might result in late “catch-up” (3–6). However, this phe-
nomenon of late luminal narrowing has not been fully
characterized for the different types of DES and its clinical
influence is yet to be established.
Using serial intravascular ul-
trasound (IVUS), we sought to
assess the temporal course of
NIH formation following im-
plantation of 2 different genera-
tions of DES with durable and
degradable polymers.
Methods
Study design and patient selection.
Patients included in this study
represent our single center initial
experience with sirolimus-eluting
stent (SES) (Cypher, Cordis Cor-
poration, Miami Lakes, Florida)
and biolimus-eluting stent (BES)
(Biomatrix, Biosensors, Singapore,
Republic of Singapore) and, there-
fore, had a noncomplex clinical
and angiographic profile (7,8).
We enrolled patients with single, de novo lesions in
native coronary arteries of reference vessel diameter
between 3.0 and 3.5 mm treated with SES and 2.75 to
4.0 mm treated with BES. Patients treated with SES
were enrolled in 2000, as a part of the first-in-man
evaluation of the Cypher stent (slow-release cohort),
whereas those receiving a BES were included in 2003. All
patients were initially assigned for invasive evaluation
with quantitative coronary angiography and IVUS right
after stent implantation and at 12-month follow-up with
SES and at 6-month follow-up with BES. In addition, all
eligible patients who did not experience a major adverse
cardiac event during follow-up were contacted and asked
to reconsent to a very late IVUS assessment (48  0.2
Abbreviations
and Acronyms
BES  biolimus-eluting
stent(s)
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
DM  diabetes mellitus
IQR  interquartile range
ISA  incomplete stent
apposition
IVUS  intravascular
ultrasound
MLD  minimal lumen
diameter
NIH  neointimal hyperplasia
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationonths in SES group, and 69  4.4 months in BESgroup). For the present report, we only included patients
with at least 3 serial IVUS acquisitions (post-procedure,
mid-term, and long-term) with appropriate image quality
for analysis and interpretation (Fig. 1).
This study complied with the Declaration of Helsinki
regarding investigation in humans and was approved by the
local ethics committee.
Study objectives and endpoint deﬁnitions. The main goal of
this study was to use serial IVUS to evaluate the temporal
course of neointimal formation after SES and BES implan-
tation, assessing whether there was significant accumulation
of intimal tissue over time.
In this regard, the primary endpoint was the compar-
ison of the percentage of NIH volume of obstruction (by
IVUS) between the 2 invasive follow-up studies (mid- vs.
long-term). The secondary endpoints included the com-
parison of vessel, lumen, and NIH variation () from
mid- to long-term follow-up between SES and BES, as
well as the impact of diabetes mellitus (DM) on NIH
formation.
Procedural characteristics. All patients were pre-treated
with clopidogrel (300 mg) or ticlopidine (500 mg) at least
24 to 48 h before the intervention. During the procedure,
intravenous heparin was given to maintain an activated
clotting time 250 s. All lesions were pre-dilated, as per
protocol. Stent implantation was performed according to
the current practice, stent length with SES was 18 mm and
BES length ranged from 8 to 28 mm. Post-dilation was
performed at the operator’s discretion. Post-procedural
aspirin was continued indefinitely, and clopidogrel (75
mg/day) or 250 mg ticlopidine (500 mg/day) was given for
only 60 days after SES implantation and 90 days after BES
implantation, as was routine at the time of the study
enrollment.
Quantitative coronary angiography analysis. Analysis of le-
ion complexity was performed in accordance with the
odified classification system of the American College of
ardiology/American Heart Association (9). Digital angio-
rams were analyzed offline using an automated edge-
etection system (QCA-CMS 5.1, Medis Medical Imaging
ystems, Leiden, the Netherlands). The quantitative angio-
raphic parameters included: 1) reference vessel diameter
RVD); 2) lesion length; 3) percentage of diameter stenosis
% DS), calculated as: [1  (MLD/RVD)]  100; and
4) late loss (difference between minimal lumen diameter
[MLD] at the end of the procedure and MLD at
follow-ups).
IVUS analysis. IVUS studies were performed immediately
ollowing the procedure and at each follow-up, after an
ntracoronary administration of 100 to 200 g of
nitroglycerin.
All IVUS studies were performed with a single-
element mechanical ultrasound catheter (Boston Scien-
tific Corporation, Natick, Massachusetts) and images
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1069were acquired by a motorized automatic transducer pull-
back system at a constant speed of 0.5 mm/s. The images
were digitalized for offline quantitative analysis according
to the American College of Cardiology’s Clinical Expert
Consensus Document on IVUS (10). Qualitative and
quantitative IVUS analyses were performed using a com-
mercially available computerized planimetry program
(EchoPlaque 3.0, Indec Systems Inc., Mountain View,
California).
Quantitative parameters of lumen, stent, and vessel
(external elastic membrane) cross-sectional areas were
measure every 1 mm. Lumen, stent, and vessel volumes
were calculated using the Simpson rule. NIH volume was
calculated by the difference between stent and lumen
volumes at each follow-up. The percentage of NIH
volume of obstruction was calculated as: neointimal
volume divided by stent volume  100. Peristent plaque
volume was defined as the difference between the vessel
FIM Cypher 
(n=15) 
Early IVUS FU 
(n=14) 
Late IVUS FU 
(n=13) 
1 patient refused  angiography 
1 patient refused angiography 
25 pa
 (12  SES a
1 inadequate/damaged image 
2000 
12-month 
48-month 
0 MACE 
Figure 1. Study Design
For this analysis, we included patients randomized in the ﬁrst-in-man (FIM) stu
(BES), who are free from any major adverse cardiac events (MACE) (death, myo
vascular ultrasound (IVUS) acquisitions. FU  follow-up.and stent volumes. In addition, all volumes were indexed oaccording to the length of the stent and expressed as
mm3/mm. Neointima-free frame ratio (given as a per-
entage) was calculated as the number of frames without
VUS-detectable neointima divided by the total number
f frames within the stent. Additionally, to evaluate the
xial distribution of NIH, we divided each stent into 3
egments and aligned subsections to correct the difference
f stent length. NIH volumes were then reported for each
ubsection and compared between follow-ups.
Stent edge dissection and incomplete stent apposition
ISA) were assessed by qualitative IVUS analysis. We
dentified ISA as 1 or more struts clearly separated from the
essel wall with evidence of blood speckles behind the strut.
hen, ISA was classified as “persistent,” “resolved,” or
late-acquired” (11).
All images were analyzed by 2 experienced operators
linded to time of the procedure at the Cardiovascular
esearch Center Angiographic and Intravascular Core Lab-
FIM Biolimus A9 
(n=32) 
Early IVUS FU 
(n=32) 
Late IVUS FU 
(n=14) 
13 patients refused angiography 
 5 MACE: 2 deaths, 3 TLRs 
ts 
3 BES) 
1 inadequate/damaged image 
2003 
6-month 
69-month 
f sirolimus-eluting stents (SES) (slow release) and biolimus-eluting stents
l infarction, and target lesion revascularization [TLR]), with at least 3 serial intra-tien
nd 1
dies o
cardiaratory in São Paulo, Brazil.
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1070Statistical analysis. Continuous variables are presented as
mean  SD or median (interquartile range [IQR]), and
categorical variables were presented as percentages. Cat-
egorical variables were compared using the Pearson
chi-square test or Fisher exact test. The Mann-Whitney
U test was used to compare continuous variables. Com-
parisons among baseline, first follow-up, and second
follow-up were performed using the Friedman test.
Additional comparisons between mid- and long-term
follow-ups were done using the Wilcoxon signed rank
test. A p value 0.05 was considered statistically signif-
icant. Intraobserver and interobserver agreements were
measured by calculating the Cohen kappa value. The data
were analyzed with the SPSS software (version 16.0,
SPSS Inc., Chicago, Illinois).
Results
Patient characteristics. Overall population consisted of 25
patients (12 SES and 13 BES). Invasive assessment was
available for all patients at a mean time of 8.7 3.2 months
for mid-term follow-up and 59.7  11.4 months for
long-term follow-up; early and late follow-up periods were
significantly different between groups (p  0.001 for both
follow-up periods).
Mean age was 59 years and 28% of patients had DM.
Hypertension and hypercholesterolemia were more fre-
quent in the BES group, with no other significant
differences between groups. Stable coronary syndrome
was the initial clinical indication for the majority of the
cases (88%).
Most lesions (64%) were classified as B2/C, according
to the American College of Cardiology/American Heart
Association definition. The left anterior descending ar-
tery was the most frequently treated vessel (52%). Mean
reference vessel diameter and lesion length were 2.96 
0.4 mm and 13.7  1.9 mm, respectively; other baseline
clinical and angiographic characteristics are presented in
Table 1. Angiographic late loss was 0.16  0.18 at
mid-term follow-up and 0.26  0.19 at long-term
follow-up (Table 2).
Quantitative IVUS analysis. Overall, the percentage of NIH
volume of obstruction significantly increased from mid- to
long-term follow-ups (mean: 1.3% at first follow-up vs.
4.8% at second follow-up, median: 0.3% [IQR: 0% to 1.3%]
vs. 1.9% [IQR: 0.8% to 8.9%], p  0.002), along with a
significant NIH volume increase from 1.8 to 6.3 mm3
(median: 0.7 mm3 [IQR: 0.1 to 1.9 mm3] to 3.4 mm3 [IQR:
0.9 to 10.3 mm3], p  0.005) (Table 3), this NIH increase
was evenly distributed among the subsegments of the stents
(Fig. 2). The kappa values for intraobserver and interob-
server agreements of NIH volume were 0.89 and 0.86,
respectively.There were no significant differences in the variation of
vessel volume index (  0.70 mm3/mm BES vs.  
0.18 mm3/mm SES, p  0.56), lumen volume index
  0.40 mm3/mm BES vs.   0.05 mm3/mm
SES, p  0.71), and percentage of NIH volume of
obstruction (  3.0% BES vs.   3.8% SES, p  0.55)
between DES (Table 4, Fig. 3).
In a separate analysis, sorting out patients according to
diabetic status (7 diabetics and 18 nondiabetics), a more
pronounced NIH increase among diabetics was found
(mean NIH volume at second follow-up: 10.15  5.6
mm3 DM vs. 5.11  6.4 mm3 non-DM, p  0.028; mean
% NIH volume of obstruction at second follow-up: 8.3 
5.6% DM vs. 3.5  4.4% non-DM, p  0.022) (Fig. 4).
Qualitative IVUS analysis. Table 5 summarizes the results of
he qualitative analysis. In the BES group, ISA was ob-
erved in 2 cases at the index procedure and persisted until
he last evaluation. There were no cases of acquired ISA in
he SES group.
iscussion
The present analysis represents the longest available
invasive follow-up of different DES technologies and
confirms the slight but significant increase in NIH
Table 1. Clinical and Angiographic Characteristics
Variable
Overall
(n  25)
SES
(n  12)
BES
(n  13) p Value
Age, yrs 58.8 7.6 55.7 7.8 61.7 6.3 0.060
Male 13 (52) 8 (66.7) 5 (38.5) 0.238
Hypertension 21 (84) 8 (66.7) 13 (100) 0.039
Family history of CAD 5 (20) 2 (16.7) 3 (23.1) 1.000
Hypercholesterolemia 16 (64) 5 (41.7) 11 (84.6) 0.041
Diabetes mellitus 7 (28) 2 (16.7) 5 (38.5) 0.378
Current smoking 4 (16) 1 (8.3) 3 (23.1) 0.593
Previous myocardial infarction 11 (44) 6 (50) 5 (38.5) 0.695
Treated vessel
LAD 13 (52) 9 (75) 4 (30.7) 0.088
LCX 6 (24) 2 (16.6) 4 (30.7)
RCA 6 (24) 1 (8.3) 5 (38.4)
Clinical presentation
Stable angina 22 (88) 10 (83.3) 12 (92.3) 0.429
Unstable angina 3 (12) 2 (16.7) 1 (7.7)
Acute myocardial infarction 0 0 0
B2/C type lesions* 16 (64) 10 (83.3) 6 (46.1) 0.129
Lesion length, mm 13.7 1.9 12.9 1.9 14.5 2.0 0.052
Reference vessel diameter, mm 2.96 0.4 2.98 0.4 2.95 0.3 0.833
Diameter stenosis, % 63.1 8.2 62.0 7.0 64.2 9.1 0.507
Values are mean  SD or n (%). *Wilcoxon signed rank test. The p values are for the overall
population.
BESbiolimus-eluting stent(s); CAD coronary artery disease; LAD left anterior descending
artery; LCX left circumflex artery; RCA right coronary artery; SES sirolimus-eluting stent(s).formation after DES implantation, with this augment
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1071being similar between SES and BES and more pro-
nounced among diabetic patients.
Although slow and progressive, NIH growth in DES is
likely related to ongoing arterial repair (12,13). Persistent
Table 2. Quantitative Coronary Angiography Analysis
Groups
From Post-Procedural to
First Follow-Up
SES, n  12 0.10 0.21
BES, n  13 0.20 0.11
All patients 0.16 0.18
p value (SES vs. BES) 0.16
Values are mean SD.
LL late loss; other abbreviations as in Table 1.
Table 3. Overall Cohort In-Stent Serial 3-Dimensional IVUS
Volumetric Analysis
Variable
Post-
Procedure
Mid-Term
Follow-Up
Long-Term
Follow-Up
VVI, mm3/mm 16.4 4.7 15.7 4.1 15.1 3.6
Median (IQR) 15.7 (12.6–19.6) 15.1 (12.6–17.9) 15.4 (12.5–18.1)
SES 16.2 6.2 14.2 4.7 14.4 4.2
15.1 (11.9–20.1) 12.8 (10.8–16.6) 13.7 (11.–17.5)
BES 16.6 3.3 17.0 3.0 15.8 2.8
16.4 (14.6–19.4) 17.2 (14.8–19.6) 16.1 (13.2–18.1)
PVI, mm3/mm 7.5 2.3 7.7 2.7 7.6 2.2
Median (IQR) 7.2 (6.0–8.4) 7.4 (5.5–9.0) 7.5 (5.6–8.5)
SES 7.2 2.4 7.0 3.4 7.2 2.8
7.0 (5.9–8.3) 5.9 (5.1–8.3) 7.1 (5.5–7.8)
BES 7.7 2.3 8.4 1.7 8.0 1.4
7.2 (6.2–8.9) 8.7 (7.2–9.1) 8.2 (7.3–9.0)
LVI, mm3/mm 8.2 1.7 7.8 1.6 7.5 1.7
Median (IQR) 8.0 (6.8–8.8) 7.8 (6.7–9.0) 7.5 (6.2–8.6)
SES 7.9 2.1 7.2 1.5 7.2 1.7
7.3 (6.3–8.7) 7.1 (5.7–8.2) 7.1 (5.7–8.3)
BES 8.3 1.5 8.3 1.6 7.8 1.7
8.2 (7.1–9.2) 8.2 (7.3–9.3) 7.6 (6.2–8.8)
NIH volume, mm3 0 1.8 2.9 6.3 6.5
Median (IQR) 0.7 (0.1–1.9) 3.4 (0.9–10.3)
SES 0 2.5 3.7 7.7 6.7
1.0 (0.4–2.6) 7.7 (1.0–13.0)
BES 0 1.2 2.0 4.9 6.3
0.4 (0–1.5) 1.4 (0.9–7.8)
% NIH obstruction 0 1.3 2.3 4.8 5.1
Median (IQR) 0.3 (0–1.3) 1.9 (0.8–8.9)
SES 0 1.9 3.1 5.7 4.8
3.1 (0–1.7) 5.5 (1.0–10.0)
BES 0 0.7 1.1 3.8 5.5
0.2 (0–1.0) 0.9 (0.8–5.8)
Values are mean SD or median (interquartile range [IQR]).
LVI lumen volume index; NIH neointimal hyperplasia; PVI plaque volume index; VVIvessel volume index; other abbreviations as in Table 1.fibrin and inflammation around stent struts had been found
beyond the duration of drug release in first-generation
DES. Nonerodible polymers used in SES are associated
with chronic inflammation and, in particular, with eosino-
phils infiltration (14,15). Conversely, the biodegradable
polymer present in the BES (polylactic acid) has proved to
evoke less but still some response compared with durable
polymers; although the presence of parent polymer com-
pound (parylene C) in BES and polylactide biodegradation
products are possible mechanisms that could induce inflam-
mation, this has not been investigated (16,17). This chronic
inflammatory response results in the release of various
growth factors that might induce late smooth cell prolifer-
ation and migration, resulting in continuous hyperplasia
accumulation.
LL, mm
m Post-Procedural to
Second Follow-Up
Delayed LL (Between First
and Second Follow-Ups)
0.21 0.32 0.11 0.22
0.29 0.14 0.09 0.13
0.26 0.19 0.10 0.10
0.43 0.89
Figure 2. Schematic Representation of NIH Distribution
In the midterm follow-up (FU) (light blue), the amount of neointimal
hyperplasia (NIH) developed was evenly distributed among portions of the
stent. In the long-term FU (dark blue), one can notice that the amount ofFroNIH signiﬁcantly increases in all 3 segments of the stent.
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1072Our results are consistent with previous publications
assessing the occurrence of this phenomenon after DES
implantation using different surrogates. Recently, Byrne et
al. (18), assessing 805 lesions with serial quantitative coro-
nary angiography evaluation (6 to 8 months and 2 years),
identified a mild but significant increase in late loss between
early and late follow-ups among patients treated with both
SES and Xience V everolimus-eluting stent (Abbott Vas-
cular, Redwood City, California). Moreover, Kuriyama et
al. (19), in a similar study design, using SES with early (8
months) and late (2 years) angiographic follow-up, report a
significant decrease in MLD (from 2.56 to 2.35 mm, p 
0.001) with a late restenosis rate of 7.1%. Conversely, after
bare-metal stent (BMS) implantation, serial IVUS assess-
Table 4. 3-Dimensional IVUS Variations From First to
Variable
Ov
(n 
∆VVI, mm3/mm 0.23
Median (IQR) 0.4 (
∆PVI, mm3/mm 0.01
Median (IQR) 0.002 (
∆LVI, mm3/mm 0.22
Median (IQR) 0.2 (
∆NIH volume, mm3 4.4
Median (IQR) 1.2 (0.5
∆% NIH obstruction 3.4
Median (IQR) 1 (0 t
Neointima-free frame ratio at 2nd follow-up, % 55.5
Values are mean SD.
Abbreviations as in Tables 1 and 3.
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Figure 3. NIH Percent Volume of Obstruction in Patients With
SES and BES
NIH percentage of obstruction at long-term follow-up in BES- (blue bar)
and SES- (green bar) treated patients. Box plots indicate median, inter-
quartile range (range from the 25th to the 75th percentile), and total range
(p  0.525). Abbreviations as in Figures 1 and 2.ment has shown that following an initial (6 to 12 months)
healing response, NIH volume remains unchanged (20).
hese findings are consistent with pathological data using
he porcine model; after 30 days, no further NIH increases
re seen after BMS implantation, as opposed to the contin-
ous growth seen with DES (13).
The late “catch-up” phenomenon has been shown to have
linical repercussion following first-generation DES, with
ew very long-term clinical studies designed to assess
hether an increasing rate of TLR is seen with DES versus
MS after the first year of implantation. The j-Cypher
egistry showed a significant increase in late TLR with SES
ompared with BMS after the first 12 months. Whereas a
ising curve was observed with SES, a plateau was seen with
nd Follow-Up in SES and BES
SES
(n  12)
BES
(n  13) p Value
0.18 3.0 0.70 2.2 0.566
.2) 0.5 (1.7 to 2.5) 0.4 (2.0 to 1.6)
0.2 2.1 0.2 1.3 0.755
.3) 0.3 (1.1 to 1.8) 0.2 (1.3 to 0.7)
0.05 1.2 0.40 0.9 0.713
.7) 0.3 (0.9 to 0.9) 0.2 (0.8 to 0.1)
5.2 7.4 3.6 6.2 0.755
) 1.9 (0.5 to 10.6) 1.1 (0.1 to 7.2)
3.8 4.9 3.0 5.6 0.551
1.0 (0 to 7.7) 0.7 (0.07 to 5.7)
2 43.7 35.6 68.5 26.1 0.085
Figure 4. NIH in DM and Non-DM
A marked increase in percent of neointimal hyperplasia (NIH) obstruction
was observed in diabetic patients compared with nondiabetic patients atSeco
erall
25)
 2.6
1.8 to 2
 1.7
1.1 to 1
 1.0
0.8 to 0
 6.7
to 9.3
 5.2
o 6.2)
 33.second follow-up. DM  diabetes mellitus.
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1073BMS through 3 years of follow-up (21). This pattern of
BMS NIH stabilization has been previously described by
Yamaji et al. (22).
Furthermore, DES 5-year TLR curves for SES and
paclitaxel-eluting stents (Boston Scientific) and 3-year data
on everolimus-eluting stents and BES showed a delayed
need for reintervention after the first year that continue in a
rising fashion throughout the follow-up period (23–27).
Among the DES, a possible exception could be the En-
deavor zotarolimus-eluting stent (Medtronic Cardiovascu-
lar, Santa Rosa, California), because the 5-year TLR curve
of this DES is similar (“flat” pattern) to BMS after the first
12 months of follow-up, suggesting no late “catch-up” with
this device (28). The phosphorylcholine carrier used on the
Endeavor stent, with its passive properties, might play a role
in the lack of continuous local inflammation.
Five-year follow-up of patients in randomized clinical
trials has identified age and diabetes as clinical predictors of
long-term TLR after first-generation DES implantation
(25,29). In addition, diabetes, chronic occlusion, ostial
lesion location, and pre-procedure reference diameter pre-
dicted delayed NIH progression and MLD erosion (5).
Kuriyama et al. (19) recognized MLD at early follow-up as
an independent predictor of late restenosis. In our cohort,
using IVUS, we found that diabetic patients, compared with
nondiabetic patients, exhibit significantly greater NIH ac-
cumulation over time.
As a consequence of NIH increase over time, there is a
reduction of uncovered struts assessed by pathology and optical
coherence tomography (12,30). Findings after SES implanta-
tion described a late (2 years) reduction in uncovered struts
(88% to 29%, p  0.002) associated with an increase in
eointimal thickness (76.8 to 123.0 m, p  0.0001) (30).
Although limited by IVUS’s resolution (100 m) to identify
tissue covering the struts, we described IVUS frames free from
NIH in our population. There were significantly higher frames
free from NIH in mid-term compared with long-term
follow-up (88.4% vs. 55.5%, p 0.001), suggesting that NIH
growth increases strut coverage over time.
These findings suggest that NIH growth is a vascular
healing response to DES that progresses until very late
Table 5. Qualitative IVUS Analysis
Variable SES (n  12) BES (n  13) p Value
ISA at baseline 1 2 1.00
Resolved ISA 1 0 0.96
Persistent ISA 0 2 0.49
Acquired ISA 0 0 1.00
ISA at long-term follow-up 0 2 0.49
ISA incomplete stent apposition; other abbreviations as in Tables 1 and 3.phases of implantation. However, if this trend will stabilizeor late “catch-up” will occur depends on further clinical and
invasive follow-up of patients treated with DES.
Study limitations. First, this analysis refers to the relatively
mall number of patients evaluated in each group. Also, we
cknowledge a selection bias because only events-free pa-
ients were included. Second, this was a nonrandomized
omparison with differences in time of recruitment and
nvasive follow-up. In addition, invasive assessments were
one at 2 time points, which limits our ability to draw a
trong conclusion to evaluate the course of NIH between
he periods studied. Third, the device platform as well as the
resence of a primer polymer (parylene C) used in BES has
hanged, and these results might not be the same with the
urrent design (Biomatrix Flex).
onclusions
The present serial IVUS assessment represents the longest
invasive assessment of 2 generations of DES with durable
and biodegradable polymers. The findings of this study
support the occurrence of continuous NIH growth follow-
ing different generations of DES. These findings seem to be
particularly more pronounced among patients with DM.
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